Important note: Information in this article was accurate in February 2002. The state of the art may have changed since the publication date. 
The non-nuke efavirenz (Sustiva, Stocrin) is used as part of combination therapy by some people with HIV/AIDS (PHAs). Efavirenz can cause the following commonly experienced side effects:
These side effects are supposed to fade during the first four weeks of use.
Efavirenz can also have other effects. In one series of experiments, researchers gave monkeys efavirenz throughout pregnancy. They found that three of 20 (15%) of the monkeys had fetuses which had various defects. Based on these results, the use of efavirenz is not recommended for women who are pregnant.
Doctors in Rome, Italy, recently reported a case of an HIV positive woman who gave birth to a baby with birth defects. The woman had the following profile before she became pregnant:
Doctors prescribed standard doses of the following drugs:
The doctors also counselled her about the potential risks of this therapy in women of childbearing age and advised her about the use of "adequate" birth control. Sometime later, she noticed that her periods had stopped. After performing a pregnancy test, she found that she was pregnant.
On reporting her findings to her doctors, they switched her therapy to the following regimen which is considered to be less toxic to the fetus:
Both before and during her pregnancy, the woman took the B-vitamin folic acid (folate). This vitamin can help reduce the risk of some birth defects. Nonetheless she gave birth to a baby with several defects:
Ordinarily, babies with these problems can die, but thanks to surgery the myelomeningocele was removed and a shunt was placed in the brain to drain excess fluid. High-tech testing — called PCR — of the baby's blood suggested that it was not infected with HIV.
Does efavirenz cause birth defects in people? This report from the Italian doctors may well be the first case of a birth defect in a fetus accidentally exposed to efavirenz. It does not prove that efavirenz caused this type of birth defect, called a neural tube defect. The report does underscore the need for clear discussion and counselling by doctors about the potential risks and benefits of efavirenz to their HIV positive female patients who may become pregnant. If additional reports of neural tube defects in babies born to female users of efavirenz occur, then further and stronger precautions may be needed.
REFERENCES
1. Fundaró C, Genovese O, Rendeli C, et al. Myelomeningocele in a child with interuterine exposure to efavirenz. AIDS 2002;16(2):299-300.
2. Botto LD, Moore CA, Khoury MJ and Erickson JD. Neural-tube defects. New England Journal of Medicine 1999;341(20):1509-1519.
20020206
CATE-N20020206
Copyright © 2002 - TreatmentUpdate. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Editor, The Canadian AIDS Treatment Information Exchange, 555 Richmond St. West, Suite 505, Box 1104, Toronto, ON, M5V 3B1 • Phone: 416-203-7122 • Toll Free: 1-800-263-1638 • Fax: 416-203-8284 http://www.catie.ca
ÆGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
ÆGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
